Biliary Tract Cancer - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Biliary Tract Cancer

The Experts below are selected from a list of 6189 Experts worldwide ranked by ideXlab platform

Caterina Vivaldi – 1st expert on this subject based on the ideXlab platform

  • multivariate prognostic factors analysis for second line chemotherapy in advanced Biliary Tract Cancer
    British Journal of Cancer, 2014
    Co-Authors: Lorenzo Fornaro, Donatella Santini, Stefano Cereda, Giuseppe Aprile, S Di Girolamo, Nicola Silvestris, Sara Lonardi, Francesco Leone, Michele Milella, Caterina Vivaldi

    Abstract:

    Multivariate prognostic factors analysis for second-line chemotherapy in advanced Biliary Tract Cancer

  • Multivariate prognostic factors analysis for second-line chemotherapy in advanced Biliary Tract Cancer
    British Journal of Cancer, 2014
    Co-Authors: Lorenzo Fornaro, Donatella Santini, Stefano Cereda, Giuseppe Aprile, S Di Girolamo, Nicola Silvestris, Sara Lonardi, Francesco Leone, Michele Milella, Caterina Vivaldi

    Abstract:

    Background: The role of second-line chemotherapy (CT) is not established in advanced Biliary Tract Cancer (aBTC). We investigated the outcome of aBTC patients treated with second-line CT and devised a prognostic model. Methods: Baseline clinical and laboratory data of 300 consecutive aBTC patients were collected and association with overall survival (OS) was investigated by multivariable Cox models. Results: The following parameters resulted independently associated with longer OS: Eastern Cooperative Oncology Group performance status of 0 ( P

Ann W Hsing – 2nd expert on this subject based on the ideXlab platform

  • diet and Biliary Tract Cancer risk in shanghai china
    PLOS ONE, 2017
    Co-Authors: Shakira M Nelson, Leticia Nogueira, Ming Chang Shen, Bingsheng Wang, Asif Rashid, Ann W Hsing, Jill Koshiol

    Abstract:

    Trends in Biliary Tract Cancer incidence rates have increased in Shanghai, China. These trends have coincided with economic and developmental growth, as well as a shift in dietary patterns to a more Westernized diet. To examine the effect of dietary changes on incident disease, we evaluated associations between diet and Biliary Tract Cancers amongst men and women from a population-based case-control study in Shanghai, China. Biliary Tract Cancer cases were recruited from 42 collaborating hospitals in urban Shanghai, and population-based controls were randomly selected from the Shanghai Household Registry. Food frequency questionnaire data were available for 225 gallbladder, 190 extrahepatic bile duct, and 68 ampulla of Vater Cancer cases. A total of 39 food groups were created and examined for associations with Biliary Tract Cancer. Interestingly, only four food groups demonstrated a suggested association with gallbladder, extrahepatic bile duct, or ampulla of Vater Cancers. The allium food group, consisting of onions, garlic, and shallots showed an inverse association with gallbladder Cancer (OR: 0.81, 95% CI: 0.68–0.97). Similar trends were seen in the food group containing seaweed and kelp (OR: 0.79, 95% CI: 0.67–0.96). In contrast, both preserved vegetables and salted meats food groups showed positive associations with gallbladder Cancer (OR:1.27, 95% CI: 1.06–1.52; OR: 1.18, 95% CI: 1.02–1.37, respectively). Each of these four food groups showed similar trends for extrahepatic bile duct and ampulla of Vater Cancers. The results of our analysis suggest intake of foods with greater anti-inflammatory properties may play a role in decreasing the risk of Biliary Tract Cancers. Future studies should be done to better understand effects of cultural changes on diet, and to further examine the impact diet and inflammation have on Biliary Tract Cancer incidence.

  • metabolic syndrome and insulin resistance in relation to Biliary Tract Cancer and stone risks a population based study in shanghai china
    British Journal of Cancer, 2011
    Co-Authors: Fatma M Shebl, Ming Chang Shen, Bingsheng Wang, Asif Rashid, Gabriella Andreotti, Tamra E Meyer, Kai Yu, Bai He Zhang, Frank Z Stanczyk, Ann W Hsing

    Abstract:

    Metabolic syndrome and insulin resistance in relation to Biliary Tract Cancer and stone risks: a population-based study in Shanghai, China

  • chronic typhoid infection and the risk of Biliary Tract Cancer and stones in shanghai china
    Infectious Agents and Cancer, 2011
    Co-Authors: Mahboobeh Safaeian, Asif Rashid, Lori C Sakoda, Sabah M Quraishi, Bing Shen Wang, Jinbo Chen, James Pruckler, Eric D Mintz, Ann W Hsing

    Abstract:

    Previous studies have shown a positive association between chronic typhoid carriage and Biliary Cancers. We compared serum Salmonella enterica serovar Typhi antibody titers between Biliary Tract Cancer cases, Biliary stone cases without evidence of Cancer, and healthy subjects in a large population-based case-control study in Shanghai, China. Participants included 627 newly diagnosed primary Biliary Tract Cancer patients; 1,037 Biliary stone cases (774 gallbladder and 263 bile-duct) and 959 healthy subjects without a history of Cancer, randomly selected from the Shanghai Resident Registry. Overall only 6/2,293 (0.26%) were Typhi positive. The prevalence of Typhi was 1/457 (0.22%), 4/977 (0.41%), and 1/859 (0.12%) among Cancer cases, Biliary-stone cases, and population controls, respectively. We did not find an association between Typhi and Biliary Cancer in Shanghai, due to the very low prevalence of chronic carriers in this population. The low seroprevalence of S. Typhi in Shanghai is unlikely to explain the high incidence of Biliary Cancers in this population.

Takashi Sasaki – 3rd expert on this subject based on the ideXlab platform

  • current status of chemotherapy for the treatment of advanced Biliary Tract Cancer
    The Korean Journal of Internal Medicine, 2013
    Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Kazuhiko Koike

    Abstract:

    Chemotherapy is indispensable for the treatment of advanced Biliary Tract Cancer. Recently, reports regarding first-line chemotherapy have increased, and first-line chemotherapy treatment has become gradually more sophisticated. Gemcitabine and cisplatin combination therapy (or gemcitabine and oxaliplatin combination therapy) have become the standard of care for advanced Biliary Tract Cancer. Oral fluoropyrimidines have also been shown to have good antitumor effects. Gemcitabine, platinum compounds, and oral fluoropyrimidines are now considered key drugs for the treatment of advanced Biliary Tract Cancer. Several clinical trials using molecular targeted agents are also ongoing. Combination therapy using cytotoxic agents and molecular-targeted agents has been evaluated widely. However, reports regarding second-line chemotherapy remain limited, and it has not yet been clarified whether second-line chemotherapy can improve the prognosis of advanced Biliary Tract Cancer. Thus, there is an urgent need to establish second-line standard chemotherapy treatment for advanced Biliary Tract Cancer. Several problems exist when assessing the results of previous reports concerning advanced Biliary Tract Cancer. In the present review, the current status of the treatment of advanced Biliary Tract Cancer is summarized, and several associated problems are indicated. These problems should be solved to achieve more sophisticated treatment of advanced Biliary Tract Cancer.

  • a randomized phase ii study of gemcitabine and s 1 combination therapy versus gemcitabine monotherapy for advanced Biliary Tract Cancer
    Cancer Chemotherapy and Pharmacology, 2013
    Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Naoki Sasahira, Hirofumi Kogure, Nobuo Toda, Ichiro Yasuda, Keiji Hanada, Hiroyuki Maguchi, Hideki Kamada

    Abstract:

    Purpose
    In order to confirm the impact of adding S-1 to gemcitabine, we conducted a randomized phase II study to compare the combination therapy of gemcitabine plus S-1 to gemcitabine monotherapy in patients with advanced Biliary Tract Cancer.

  • Improvement of prognosis for unresectable Biliary Tract Cancer
    World Journal of Gastroenterology, 2013
    Co-Authors: Takashi Sasaki, Hiroyuki Isayama, Yousuke Nakai, Naminatsu Takahara, Naoki Sasahira, Hirofumi Kogure, Suguru Mizuno, Hiroshi Yagioka, Natsuyo Yamamoto

    Abstract:

    CONCLUSION: The prognosis of unresectable Biliary Tract Cancer has improved recently. Using three effective drugs (gemcitabine, platinum analogs, and fluoropyrimidine) may improve the prognosis of this Cancer.